Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ASHISH KAMAT and COLIN P DINNEY.
ASHISH KAMAT
Connection Strength
13.749
COLIN P DINNEY
  1. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. J Urol. 2013 Dec; 190(6):2019.
    View in: PubMed
    Score: 0.460
  2. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Gu?rin therapy for bladder cancer: results of a prospective trial. J Urol. 2012 Mar; 187(3):862-7.
    View in: PubMed
    Score: 0.411
  3. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 2011 Oct; 108(7):1119-23.
    View in: PubMed
    Score: 0.388
  4. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol. 2006 Sep; 3(9):472-3.
    View in: PubMed
    Score: 0.283
  5. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Gu?rin Have an Effect? Eur Urol. 2024 Oct; 86(4):366-368.
    View in: PubMed
    Score: 0.243
  6. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
    View in: PubMed
    Score: 0.241
  7. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int. 2024 Jun; 133(6):733-741.
    View in: PubMed
    Score: 0.238
  8. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2024 Feb; 211(2):241-255.
    View in: PubMed
    Score: 0.233
  9. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin or Early Radical Cystectomy. Eur Urol Oncol. 2023 12; 6(6):590-596.
    View in: PubMed
    Score: 0.229
  10. Bacillus Calmette-Gu?rin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal? BJU Int. 2023 10; 132(4):384-386.
    View in: PubMed
    Score: 0.227
  11. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci. 2023 Jul; 53:16-22.
    View in: PubMed
    Score: 0.225
  12. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol. 2023 02; 41(2):108.e11-108.e17.
    View in: PubMed
    Score: 0.218
  13. Reply by Authors. J Urol. 2022 08; 208(2):290-291.
    View in: PubMed
    Score: 0.212
  14. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Gu?rin Response in High-Grade Ta Tumors. J Urol. 2022 08; 208(2):284-291.
    View in: PubMed
    Score: 0.212
  15. Reduced Dose Intravesical Bacillus Calmette-Gu?rin: Why It Might Not Matter. Bladder Cancer. 2022; 8(2):113-117.
    View in: PubMed
    Score: 0.211
  16. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin. Eur Urol Oncol. 2022 02; 5(1):84-91.
    View in: PubMed
    Score: 0.204
  17. Reduced-dose bacillus Calmette-Gu?rin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre. BJU Int. 2022 09; 130(3):323-330.
    View in: PubMed
    Score: 0.204
  18. Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Gu?rin? BJU Int. 2022 10; 130(4):463-469.
    View in: PubMed
    Score: 0.204
  19. Reply by Authors. J Urol. 2021 11; 206(5):1267.
    View in: PubMed
    Score: 0.199
  20. Progression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021 11; 206(5):1258-1267.
    View in: PubMed
    Score: 0.198
  21. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. World J Urol. 2021 Nov; 39(11):4143-4149.
    View in: PubMed
    Score: 0.197
  22. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Gu?rin Therapy Outcomes. Eur Urol Oncol. 2022 06; 5(3):347-356.
    View in: PubMed
    Score: 0.196
  23. Reply by Authors. J Urol. 2021 06; 205(6):1620-1621.
    View in: PubMed
    Score: 0.194
  24. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 11; 128(5):568-574.
    View in: PubMed
    Score: 0.193
  25. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Gu?rin: Implications for Clinical Trial Design. J Urol. 2021 06; 205(6):1612-1621.
    View in: PubMed
    Score: 0.192
  26. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu?rin. BJU Int. 2021 07; 128(1):65-71.
    View in: PubMed
    Score: 0.190
  27. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.190
  28. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
    View in: PubMed
    Score: 0.152
  29. Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer. 2017 Jul 27; 3(3):145-146.
    View in: PubMed
    Score: 0.151
  30. Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer. 2017 Jul 27; 3(3):147-148.
    View in: PubMed
    Score: 0.151
  31. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583.
    View in: PubMed
    Score: 0.150
  32. Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs R D. 2017 Jun; 17(2):297-304.
    View in: PubMed
    Score: 0.149
  33. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology. 2017; 6(2):e1265719.
    View in: PubMed
    Score: 0.145
  34. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. Medicine (Baltimore). 2016 Aug; 95(31):e4500.
    View in: PubMed
    Score: 0.141
  35. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon a2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol. 2016 11; 23(12):4110-4114.
    View in: PubMed
    Score: 0.140
  36. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Gu?rin Therapy: Implication for Clinical Trial Design. Eur Urol. 2016 11; 70(5):778-785.
    View in: PubMed
    Score: 0.137
  37. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol. 2016 Feb; 34(2):59.e1-8.
    View in: PubMed
    Score: 0.133
  38. Novel fluorescence in?situ hybridization-based definition of bacille Calmette-Gu?rin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int. 2016 May; 117(5):754-60.
    View in: PubMed
    Score: 0.131
  39. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Gu?rin. Eur Urol. 2016 02; 69(2):197-200.
    View in: PubMed
    Score: 0.130
  40. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34.
    View in: PubMed
    Score: 0.124
  41. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug; 32(6):826-32.
    View in: PubMed
    Score: 0.121
  42. Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int. 2014 May; 113(5b):E28-33.
    View in: PubMed
    Score: 0.120
  43. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7.
    View in: PubMed
    Score: 0.114
  44. Phase I trial of intravesical recombinant adenovirus mediated interferon-a2b formulated in Syn3 for Bacillus Calmette-Gu?rin failures in nonmuscle invasive bladder cancer. J Urol. 2013 Sep; 190(3):850-6.
    View in: PubMed
    Score: 0.111
  45. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. BJU Int. 2012 Dec; 110(11 Pt B):E590-5.
    View in: PubMed
    Score: 0.106
  46. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011 Mar; 107(6):898-904.
    View in: PubMed
    Score: 0.096
  47. Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol. 2011 Jan; 185(1):79-83.
    View in: PubMed
    Score: 0.095
  48. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol. 2012 May-Jun; 30(3):266-72.
    View in: PubMed
    Score: 0.094
  49. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol. 2011 Mar-Apr; 29(2):157-61.
    View in: PubMed
    Score: 0.091
  50. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer. 2010 Jan 15; 116(2):340-6.
    View in: PubMed
    Score: 0.089
  51. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009 Dec; 28(3-4):335-44.
    View in: PubMed
    Score: 0.089
  52. Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009 Jun; 9(6):807-13.
    View in: PubMed
    Score: 0.086
  53. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology. 2009 Jan; 73(1):147-52.
    View in: PubMed
    Score: 0.082
  54. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol. 2008 Jul; 180(1):164-7; discussion 167.
    View in: PubMed
    Score: 0.080
  55. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008 Jan 01; 26(1):121-6.
    View in: PubMed
    Score: 0.078
  56. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9.
    View in: PubMed
    Score: 0.076
  57. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology. 2007 Aug; 70(2):252-6.
    View in: PubMed
    Score: 0.075
  58. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007 Jul 01; 110(1):62-7.
    View in: PubMed
    Score: 0.075
  59. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007 Sep; 52(3):769-74.
    View in: PubMed
    Score: 0.074
  60. Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol. 2006 Oct; 176(4 Pt 1):1642-7.
    View in: PubMed
    Score: 0.071
  61. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer. 2006 Oct 01; 107(7):1491-5.
    View in: PubMed
    Score: 0.071
  62. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol. 2006 Jul; 176(1):53-7; discussion 57.
    View in: PubMed
    Score: 0.070
  63. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006 Jun; 175(6):2058-62.
    View in: PubMed
    Score: 0.070
  64. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006 Mar; 175(3 Pt 1):881-5.
    View in: PubMed
    Score: 0.068
  65. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 Sep 01; 4(9):2444-2453.
    View in: PubMed
    Score: 0.062
  66. Focus on bladder cancer. Cancer Cell. 2004 Aug; 6(2):111-6.
    View in: PubMed
    Score: 0.061
  67. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004 Mar; 3(3):279-90.
    View in: PubMed
    Score: 0.060
  68. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
    View in: PubMed
    Score: 0.058
  69. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2023; 9(3):271-286.
    View in: PubMed
    Score: 0.058
  70. Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.
    View in: PubMed
    Score: 0.057
  71. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Gu?rin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023 10; 6(5):531-534.
    View in: PubMed
    Score: 0.057
  72. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res. 2003 Jul; 9(7):2786-97.
    View in: PubMed
    Score: 0.057
  73. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. J Urol. 2023 08; 210(2):254-255.
    View in: PubMed
    Score: 0.056
  74. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol. 2023 01; 209(1):140-149.
    View in: PubMed
    Score: 0.054
  75. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.
    View in: PubMed
    Score: 0.053
  76. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2022 04; 20(2):176-182.
    View in: PubMed
    Score: 0.051
  77. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
    View in: PubMed
    Score: 0.051
  78. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. J Urol. 2022 Mar; 207(3):551-558.
    View in: PubMed
    Score: 0.051
  79. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass. 2022 Jan; 3(1):37-44.
    View in: PubMed
    Score: 0.050
  80. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology. 2021 11; 157:181-187.
    View in: PubMed
    Score: 0.049
  81. Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. Bladder Cancer. 2021 May 25; 7(2):243-252.
    View in: PubMed
    Score: 0.049
  82. Time interval from transurethral resection of bladder tumour to bacille Calmette-Gu?rin induction does not impact therapeutic response. BJU Int. 2021 11; 128(5):634-641.
    View in: PubMed
    Score: 0.049
  83. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol. 2021 Sep; 206(3):577-585.
    View in: PubMed
    Score: 0.049
  84. Oncologic Equipoise Between Robotic and Open Radical Cystectomy. J Endourol. 2021 08; 35(8):1168-1176.
    View in: PubMed
    Score: 0.049
  85. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol. 2021 04; 39(4):237.e1-237.e5.
    View in: PubMed
    Score: 0.048
  86. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.047
  87. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. J Sex Med. 2020 10; 17(10):1995-2004.
    View in: PubMed
    Score: 0.046
  88. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol. 2020 07 07; 154(2):208-214.
    View in: PubMed
    Score: 0.046
  89. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
    View in: PubMed
    Score: 0.046
  90. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol. 2020 04; 38(4):247-254.
    View in: PubMed
    Score: 0.045
  91. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798.
    View in: PubMed
    Score: 0.044
  92. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891.
    View in: PubMed
    Score: 0.044
  93. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Gu?rin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. J Urol. 2020 02; 203(2):283-291.
    View in: PubMed
    Score: 0.044
  94. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.
    View in: PubMed
    Score: 0.043
  95. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol. 2019 Dec; 37(12):2691-2698.
    View in: PubMed
    Score: 0.042
  96. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol. 2019 01; 75(1):8-10.
    View in: PubMed
    Score: 0.041
  97. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2019 05; 2(3):286-293.
    View in: PubMed
    Score: 0.041
  98. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus. 2020 01 15; 6(1):88-94.
    View in: PubMed
    Score: 0.040
  99. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034.
    View in: PubMed
    Score: 0.040
  100. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 09; 79:57-65.
    View in: PubMed
    Score: 0.040
  101. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int. 2018 07; 122(1):89-98.
    View in: PubMed
    Score: 0.040
  102. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov. 2018 Jun; 25(3):242-250.
    View in: PubMed
    Score: 0.039
  103. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int. 2018 02; 121(2):244-251.
    View in: PubMed
    Score: 0.038
  104. Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Gu?rin. Oncotarget. 2017 Oct 24; 8(51):88782-88791.
    View in: PubMed
    Score: 0.038
  105. High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol. 2017 09; 67:126-133.
    View in: PubMed
    Score: 0.038
  106. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953.
    View in: PubMed
    Score: 0.038
  107. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506.
    View in: PubMed
    Score: 0.037
  108. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018 09; 4(5):720-724.
    View in: PubMed
    Score: 0.036
  109. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017 05; 119(5):684-691.
    View in: PubMed
    Score: 0.036
  110. Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 04; 3(2-3):258-264.
    View in: PubMed
    Score: 0.035
  111. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202.
    View in: PubMed
    Score: 0.035
  112. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016 10; 70(4):611-620.
    View in: PubMed
    Score: 0.034
  113. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. 2016 Mar 15; 25(6):1203-14.
    View in: PubMed
    Score: 0.034
  114. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na?ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62.
    View in: PubMed
    Score: 0.033
  115. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec; 46(12):1808-14.
    View in: PubMed
    Score: 0.033
  116. Genetic Variants in the Wnt/?-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. J Urol. 2015 Dec; 194(6):1771-6.
    View in: PubMed
    Score: 0.033
  117. Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. Cancer Prev Res (Phila). 2015 Jul; 8(7):607-13.
    View in: PubMed
    Score: 0.032
  118. Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. Bladder Cancer. 2015 Mar 30; 1(1):29-30.
    View in: PubMed
    Score: 0.032
  119. Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]. Eur Urol. 2015 Jul; 68(1):171.
    View in: PubMed
    Score: 0.032
  120. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71.
    View in: PubMed
    Score: 0.031
  121. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology. 2014 Nov; 84(5):1147-51.
    View in: PubMed
    Score: 0.031
  122. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33.
    View in: PubMed
    Score: 0.031
  123. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014 Jul; 45(7):1466-72.
    View in: PubMed
    Score: 0.030
  124. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9.
    View in: PubMed
    Score: 0.030
  125. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 2014 Apr; 83(4):863-7.
    View in: PubMed
    Score: 0.030
  126. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol. 2013 Nov-Dec; 39(6):817-22.
    View in: PubMed
    Score: 0.029
  127. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014 Mar 01; 23(5):1387-98.
    View in: PubMed
    Score: 0.029
  128. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br J Cancer. 2013 Jun 11; 108(11):2372-80.
    View in: PubMed
    Score: 0.028
  129. Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One. 2012; 7(12):e51758.
    View in: PubMed
    Score: 0.027
  130. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7.
    View in: PubMed
    Score: 0.027
  131. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther. 2012 Nov; 13(13):1325-38.
    View in: PubMed
    Score: 0.027
  132. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Gu?rin. PLoS One. 2012; 7(6):e38533.
    View in: PubMed
    Score: 0.026
  133. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13.
    View in: PubMed
    Score: 0.026
  134. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011 Nov 01; 20(21):4282-9.
    View in: PubMed
    Score: 0.025
  135. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6.
    View in: PubMed
    Score: 0.024
  136. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila). 2011 Apr; 4(4):514-21.
    View in: PubMed
    Score: 0.024
  137. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol. 2012 Nov-Dec; 30(6):821-4.
    View in: PubMed
    Score: 0.024
  138. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology. 2011 Jul; 78(1):61-7.
    View in: PubMed
    Score: 0.024
  139. Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. AJR Am J Roentgenol. 2010 Oct; 195(4):959-65.
    View in: PubMed
    Score: 0.023
  140. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila). 2010 Oct; 3(10):1235-45.
    View in: PubMed
    Score: 0.023
  141. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010 Jul 01; 116(13):3127-34.
    View in: PubMed
    Score: 0.023
  142. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology. 2010 Dec; 76(6):1419-24.
    View in: PubMed
    Score: 0.023
  143. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May; 105(10):1402-12.
    View in: PubMed
    Score: 0.022
  144. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol. 2010 Mar; 183(3):929-34.
    View in: PubMed
    Score: 0.022
  145. Management of urethral recurrence after orthotopic urinary diversion. BJU Int. 2010 Jul; 106(1):56-61.
    View in: PubMed
    Score: 0.022
  146. Cardiac history and risk of post-cystectomy cardiac complications. Urology. 2009 Nov; 74(5):1085-9.
    View in: PubMed
    Score: 0.022
  147. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9.
    View in: PubMed
    Score: 0.022
  148. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2090-7.
    View in: PubMed
    Score: 0.022
  149. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009 Oct; 40(10):1448-52.
    View in: PubMed
    Score: 0.021
  150. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009 Jun 01; 27(16):2592-7.
    View in: PubMed
    Score: 0.021
  151. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.019
  152. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007 Dec; 178(6):2302-6; discussion 2307.
    View in: PubMed
    Score: 0.019
  153. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis. 2007 Oct; 28(10):2160-5.
    View in: PubMed
    Score: 0.019
  154. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol. 2007 Jan-Feb; 25(1):38-45.
    View in: PubMed
    Score: 0.018
  155. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? BJU Int. 2006 Dec; 98(6):1176-80.
    View in: PubMed
    Score: 0.018
  156. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther. 2006 Dec; 5(12):3032-41.
    View in: PubMed
    Score: 0.018
  157. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol. 2006 Oct; 176(4 Pt 1):1463-7.
    View in: PubMed
    Score: 0.018
  158. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 2006 Mar; 67(3):466-71.
    View in: PubMed
    Score: 0.017
  159. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology. 2006 Mar; 67(3):518-23.
    View in: PubMed
    Score: 0.017
  160. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia. 2005 Oct; 7(10):912-20.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.